- Home
- HBM vs AKRO Comparison
HBM vs AKRO Comparison
Compare HBM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBM
- AKRO
- Stock Information
- Founded
- HBM 1927
- AKRO 2017
- Country
- HBM Canada
- AKRO United States
- Employees
- HBM N/A
- AKRO N/A
- Industry
- HBM Metal Mining
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- HBM Basic Materials
- AKRO Health Care
- Exchange
- HBM Nasdaq
- AKRO Nasdaq
- Market Cap
- HBM 3.4B
- AKRO 3.9B
- IPO Year
- HBM N/A
- AKRO 2019
- Fundamental
- Price
- HBM $8.92
- AKRO $49.65
- Analyst Decision
- HBM Hold
- AKRO Strong Buy
- Analyst Count
- HBM 1
- AKRO 8
- Target Price
- HBM $14.00
- AKRO $82.50
- AVG Volume (30 Days)
- HBM 7.0M
- AKRO 1.9M
- Earning Date
- HBM 05-12-2025
- AKRO 05-12-2025
- Dividend Yield
- HBM 0.16%
- AKRO N/A
- EPS Growth
- HBM 57.91
- AKRO N/A
- EPS
- HBM 0.39
- AKRO N/A
- Revenue
- HBM $2,091,100,000.00
- AKRO N/A
- Revenue This Year
- HBM $8.01
- AKRO N/A
- Revenue Next Year
- HBM $0.92
- AKRO N/A
- P/E Ratio
- HBM $22.69
- AKRO N/A
- Revenue Growth
- HBM 8.92
- AKRO N/A
- 52 Week Low
- HBM $5.95
- AKRO $17.86
- 52 Week High
- HBM $9.91
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- HBM 66.66
- AKRO 63.34
- Support Level
- HBM $7.94
- AKRO $44.94
- Resistance Level
- HBM $9.31
- AKRO $49.29
- Average True Range (ATR)
- HBM 0.29
- AKRO 3.33
- MACD
- HBM 0.06
- AKRO 0.67
- Stochastic Oscillator
- HBM 71.17
- AKRO 86.02
About HBM Hudbay Minerals Inc. (Canada)
Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.